BidaskClub lowered shares of GTX (NASDAQ:GTXI) from a strong-buy rating to a buy rating in a research note issued to investors on Wednesday.
A number of other research analysts also recently weighed in on GTXI. Stifel Nicolaus started coverage on shares of GTX in a research report on Thursday, November 9th. They issued a buy rating for the company. Robert W. Baird started coverage on shares of GTX in a research report on Tuesday, November 21st. They issued an outperform rating and a $17.00 price objective for the company. Zacks Investment Research downgraded shares of GTX from a hold rating to a sell rating in a research report on Wednesday, January 10th. Finally, ValuEngine raised shares of GTX from a sell rating to a hold rating in a research report on Wednesday, February 7th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $17.00.
GTX (NASDAQ:GTXI) opened at $15.55 on Wednesday. The firm has a market cap of $331.10, a price-to-earnings ratio of -8.84 and a beta of 1.78. GTX has a 12-month low of $2.73 and a 12-month high of $15.95.
GTX (NASDAQ:GTXI) last released its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.25). equities analysts predict that GTX will post -1.61 earnings per share for the current fiscal year.
In other news, CEO Marc Steven Hanover sold 7,309 shares of GTX stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $11.33, for a total value of $82,810.97. Following the completion of the transaction, the chief executive officer now owns 129,990 shares of the company’s stock, valued at approximately $1,472,786.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Henry Patton Doggrell sold 4,965 shares of GTX stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $11.33, for a total transaction of $56,253.45. Following the completion of the transaction, the vice president now directly owns 54,804 shares of the company’s stock, valued at approximately $620,929.32. The disclosure for this sale can be found here. In the last three months, insiders sold 15,364 shares of company stock valued at $174,074. Insiders own 41.20% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new stake in shares of GTX during the 2nd quarter worth about $124,000. Abingworth LLP bought a new stake in shares of GTX during the 3rd quarter worth about $2,781,000. Caxton Corp bought a new stake in shares of GTX during the 3rd quarter worth about $531,000. EAM Investors LLC bought a new stake in shares of GTX during the 4th quarter worth about $551,000. Finally, Millennium Management LLC bought a new stake in shares of GTX during the 4th quarter worth about $749,000. 11.54% of the stock is owned by institutional investors.
WARNING: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/17/gtx-gtxi-downgraded-by-bidaskclub.html.
GTX Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.